extensive public visibility and created increased awareness of ALS. In 2015, a group of ALS
organizations in the U.S., including the ALS Association, Les Turner ALS Foundation, and ALS
Therapy Development Institute, re-introduced the Ice Bucket Challenge to raise further funds and
spread awareness about ALS among population.
North America is expected to hold a dominant position in the market, increasing focus of
manufacturers on novel drug development for ALS
North America is expected to hold a dominant position in the amyotrophic lateral sclerosis treatment
market, as major companies present in the region are focusing on collaborations for product
development. For instance, in January 2018 Sangamo Therapeutics, Inc. and Pfizer Inc. collaborated
for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-
TFs) for the treatment of ALS. Companies based in emerging economies of Asia Pacific are focusing
on developing novel drugs for treatment of ALS. For instant major companies such as Mitsubishi
Tanabe Pharma Corporation and Takeda Pharmaceutical Company Ltd are developing drugs for
treatment of ALS.
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Taxonomy
The global amyotrophic lateral sclerosis treatment market is segmented on the basis of drug
type and distribution channel.
On the basis of drug type, the global amyotrophic lateral sclerosis treatment market is
segmented into:
Riluzole
Edaravone (Radicava)
On the basis of distribution channel, the global amyotrophic lateral sclerosis treatment market
is segmented into:
Hospital Pharmacies
Retail & Online Pharmacies
Key Vendors of Deep Brain Stimulation Devices Market:
In December 2017, Mitsubishi Tanabe Pharma Corporation, Order made Medical Research
Corporation and Trans Chromosomics Inc. have completed strategic collaboration for the development
of antibody drug to treat neurodegenerative diseases such as ALS. Takeda Pharmaceutical Company
Ltd. collaborated with Montreal Neurological Institute for the discovery of new drugs for ALS in the same
month. In 2016, Evotec and Celgene Corporation have entered into a strategic drug discovery for the
development of new drugs for neurodegenerative diseases such as ALS. In 2013 Janssen Research &
Development, Division of Janssen Pharmaceutica NV, and Johnson & Johnson collaborated, with three
prominent Belgian academic institutions and research centers for the discovery of new treatment drugs
for neurodegenerative diseases such as ALS.